"TESARO unearths and passionately pursues the development of biopharmaceuticals that can make a difference in the lives of cancer patients. InterWest’s deep understanding of science and development, along with their investment style, compelled us to partner with them as a foundational investor. "
LeadershipLonnie Moulder, CEO & Co-Founder
Tesaro (TSRO) is an oncology-focused biopharmaceutical company dedicated to
improving the lives of cancer patients by developing and providing safer
and more effective therapeutics and supportive care products. Since its
founding, Tesaro in-licensed Rolapitant from OPKO Health, as well as
small molecule inhibitors of Anaplastic Lymphoma Kinase from Amgen.
Tesaro plans to develop one or more compounds for oncology indications,
including the treatment of patients with non-small-cell lung cancer.